New pyridazine derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents; design, synthesis and biological evaluation.

[1]  A. El-Malah,et al.  Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents. , 2019, European journal of medicinal chemistry.

[2]  S. Ching,et al.  Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis , 2019, Cancer management and research.

[3]  M. Said,et al.  Synthesis of Some Novel 2,6‐Disubstituted Pyridazin‐3(2H)‐one Derivatives as Analgesic, Anti‐Inflammatory, and Non‐Ulcerogenic Agents , 2017, Archiv der Pharmazie.

[4]  A. El-Sayed,et al.  Synthesis of Some New Pyridazine Derivatives for Anti-HAV Evaluation , 2017, Molecules.

[5]  P. Libby,et al.  Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. , 2016, The New England journal of medicine.

[6]  L. Brubaker,et al.  Multimodal analgesia: A systematic review of local NSAIDs for non-ophthalmologic postoperative pain management. , 2016, International journal of surgery.

[7]  D. Sharma,et al.  Synthesis of 2-substituted-4-aryl-6-phenylpyridazin-3(2H)-ones as potential anti-inflammatory and analgesic agents with cardioprotective and ulcerogenic sparing effects , 2016, Medicinal Chemistry Research.

[8]  Anita Singh,et al.  Analgesic and anti-inflammatory activities of several 4-substituted-6-(3'-nitrophenyl)pyridazin-(2H)-3-one derivatives , 2013 .

[9]  A. Khlebnikov,et al.  Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists. , 2013, European journal of medicinal chemistry.

[10]  N. Khalil,et al.  Synthesis and anti-inflammatory activity of novel pyridazine and pyridazinone derivatives as non-ulcerogenic agents , 2012, Archives of Pharmacal Research.

[11]  R. Bansal,et al.  Pyridazin-3(2H)-ones: the versatile pharmacophore of medicinal significance , 2012, Medicinal Chemistry Research.

[12]  Shamim Ahmad,et al.  Synthesis and biological evaluation of some novel sulfamoylphenyl-pyridazinone as anti-inflammatory agents (Part-II) , 2012, Journal of enzyme inhibition and medicinal chemistry.

[13]  K. Abouzid,et al.  Design, synthesis, and evaluation of anti-inflammatory and ulcerogenicity of novel pyridazinone derivatives , 2011, Medicinal Chemistry Research.

[14]  E. Manivannan,et al.  Analogue-based design, synthesis and molecular docking analysis of 2,3-diaryl quinazolinones as non-ulcerogenic anti-inflammatory agents. , 2011, Bioorganic & medicinal chemistry.

[15]  M. Perretti,et al.  Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists. , 2010, Pharmacology & therapeutics.

[16]  A. Rauk,et al.  Synthesis and cyclooxygenase inhibitory activities of some N-acylhydrazone derivatives of isoxazolo[4,5-d]pyridazin-4(5H)-ones. , 2010, European journal of medicinal chemistry.

[17]  M. Alam,et al.  Synthesis and biological evaluation of some novel 6-aryl-2-(p-sulfamylphenyl)-4,5-dihydropyridazin-3(2H)-ones as anti-cancer, antimicrobial, and anti-inflammatory agents , 2010, Journal of enzyme inhibition and medicinal chemistry.

[18]  K. Abouzid,et al.  Structure-based molecular design, synthesis, and in vivo anti-inflammatory activity of pyridazinone derivatives as nonclassic COX-2 inhibitors , 2010, Medicinal Chemistry Research.

[19]  J. Holderness,et al.  6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors. , 2009, Journal of medicinal chemistry.

[20]  Edward E Knaus,et al.  Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. , 2008, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[21]  S. Solomon,et al.  Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis , 2008, Circulation.

[22]  E. Corey,et al.  Facile air oxidation of the conjugate base of rofecoxib (VioXX), a possible contributor to chronic human toxicity , 2005 .

[23]  S. Shoor,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.

[24]  G. Carter,et al.  ABT-963 [2-(3,4-Difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], A Highly Potent and Selective Disubstituted Pyridazinone Cyclooxgenase-2 Inhibitor , 2004, Journal of Pharmacology and Experimental Therapeutics.

[25]  G. Clementi,et al.  Effects of centrally of peripherally injected adrenomedullin on reserpine-induced gastric lesions. , 1998, European journal of pharmacology.

[26]  C. Koboldt,et al.  1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. , 1997, Journal of medicinal chemistry.

[27]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.

[28]  R. Soliman.  Preparation and antidiabetic activity of some sulfonylurea derivatives of 3,5-disubstituted pyrazoles. , 1979, Journal of medicinal chemistry.

[29]  M. Sato,et al.  A new nonsteroidal analgesic-antiinflammatory agent. Synthesis and activity of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone and related compounds. , 1979, Journal of medicinal chemistry.

[30]  C A WINTER,et al.  Carrageenin-Induced Edema in Hind Paw of the Rat as an Assay for Antiinflammatory Drugs , 1962, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.